KBL Merger Corp. IV (KBLM), filed a definitive proxy this morning for their upcoming shareholder vote to extend their termination date another six months. However, KBLM has further amended the proxy to now reflect a $0.0225 per month contribution for shareholders who do not redeem.
Originally, KBLM agreed to contribute $0.03 for each public share that was not redeemed for each calendar month commencing on June 7, 2019, through September 7, 2019 (should they need the full three months). However, given where KBLM is in their negotiation process with CannBioRx, they are now asking for a potential six months, which would move their potential deadline date to December 7th instead.
KBLM’s preliminary proxy for their June 5th vote (filed 5/8) stated a $0.025 per month contribution, but this is now amended to reflect $0.0225. This change means that should KBLM need the full six months, the total contribution is now $0.135, down from $0.15.
The record date is still May 15th, however, it should be noted that KBLM is requiring shareholders to vote either “for” or “against” the extension proposal in order to redeem. That means that only shareholders of record will be able to redeem for their pro rata per share portion of the trust.
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...